<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161914</url>
  </required_header>
  <id_info>
    <org_study_id>ISU302-2008</org_study_id>
    <nct_id>NCT01161914</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease</brief_title>
  <official_title>A Multi-national Randomized Double Blinded Phase III Study to Evaluate the Safety and Efficacy of ISU302(Imiglucerase for Injection) or Cerezyme in Patient With Type I Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ISU Abxis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ISU Abxis Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare and evaluate the efficacy and safety of ISU302, an&#xD;
      investigational product, and Cerezyme®, comparator, for Type 1 Gaucher Disease patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in splenic volume compared to baseline</measure>
    <time_frame>one year</time_frame>
    <description>Primary endpoints to demonstrate non-inferiority of ISU302 against Cerezyme® for change in splenic volume compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in organ parameters and biochemical value compared to baseline</measure>
    <time_frame>one year</time_frame>
    <description>Change in splenic volume compared to baseline for all subjects enrolled&#xD;
Change in hemoglobin concentration&#xD;
Change in platelet counts&#xD;
Change in liver volume compared to baseline&#xD;
Change in range variation of liver function test (ALT/AST)&#xD;
Change in skeletal status improvement level&#xD;
Change in bone mineral density&#xD;
Change in biomarkers (acid phosphatase, angiotensin-converting enzyme (ACE) and chitotriosidase)&#xD;
After the 1st administration, to evaluate pharmacokinetic profile by glucocerebrosidase activity assay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>Cerezyme®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 U/kg infusion (every 2 weeks for 24 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISU302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 U/kg infusion (every 2 weeks for 24 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerezyme®</intervention_name>
    <description>administered by IV infusion for a dose of 60 U/kg</description>
    <arm_group_label>Cerezyme®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISU302</intervention_name>
    <description>administered by IV infusion for a dose of 60 U/kg</description>
    <arm_group_label>ISU302</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subjects have a diagnosis of Type I Gaucher Disease&#xD;
&#xD;
          -  Subjects between 2 years old and 75 years old&#xD;
&#xD;
          -  Subjects documented with glucocerebrosidase deficiency&#xD;
&#xD;
          -  Subjects with splenomegaly (as indicated by CT volumetric analysis as 5 times over&#xD;
             than the standard size (0.2% of total body weight in kilograms))&#xD;
&#xD;
          -  A hemoglobin concentration level:Male &gt; 12 years of age &lt;12.0 g/dL Female&gt;12 years of&#xD;
             age&lt;11.0 g/dL Child &gt; 2 years of age and &lt;12 years of age &lt;10.5 g/dL&#xD;
&#xD;
          -  Platelet count of &lt; 120,000 / ㎣&#xD;
&#xD;
          -  Treatment-naive to enzyme replacement therapy (ERT) or treatment- experienced subjects&#xD;
             who have not received ERT in the 12 months before screening and antibody test result&#xD;
             is negative&#xD;
&#xD;
          -  Treatment naive to substrate reduction therapy (SRT) or treatment- experienced&#xD;
             subjects who have not received SRT in the 12 months before screening&#xD;
&#xD;
          -  Subjects or their spouses who provide consent to use one of following contraception&#xD;
             methods, or women in menopause. (In this case, menopause is defined as a period after&#xD;
             12 months from the last menstruation)&#xD;
&#xD;
          -  Condoms, sponge, foams, jellies, diaphragm, or intrauterine device (Spouse or patient&#xD;
             who had vasectomy or tubal ligation/ hysterectomy)&#xD;
&#xD;
          -  Total abstinence from sexual intercourse: Female patient using oral contraceptives&#xD;
             must use other contraception method (barrier method) also during the trial period and&#xD;
             after the completion of trial as well as up to 90 days from the conclusion of trial.&#xD;
&#xD;
          -  The subject or their legal representative has signed the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any investigational product in 90 days before study entry&#xD;
&#xD;
          -  Partial or total splenectomy&#xD;
&#xD;
          -  Subjects who have a serious concurrent disease like infection or who abuse addictive&#xD;
             drug and substances.&#xD;
&#xD;
          -  Pregnant and/or breast-feeding women&#xD;
&#xD;
          -  Presence of Hepatitis B surface antigen or Hepatitis C or the patients show positive&#xD;
             reaction to human immunodeficiency virus (HIV) type1&#xD;
&#xD;
          -  Subjects with a history of allergic reaction to Imiglucerase&#xD;
&#xD;
          -  Subjects with a history of severe pulmonary hypertension caused by Gaucher Disease&#xD;
&#xD;
          -  Any subject whom the investigator or the sub investigator considers as inad equate for&#xD;
             this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>July 11, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2010</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <name_title>Lee, JaeHeung</name_title>
    <organization>ISU ABXIS CO., LTD</organization>
  </responsible_party>
  <keyword>Type I Gaucher</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

